LEQEMBI(R) (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

TOKYO and CAMBRIDGE, Mass., September 8, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the anti-amyloid beta (Aβ) protofibril antibody LEQEMBI® (generic name: lecanemab)…

Hitachi launches HMAX Cyber, an operational resilience service supporting business continuity in the AI era

TOKYO, September 8, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE:6501, "Hitachi"), today announced the launch of “HMAX Cyber” (“the service”), a new operational resilience service that protects enterprise systems from increasingly sophisticated cyberattacks and supports business continuity. The service is one of the Foundry Solutions that support…

Transgene and NEC Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications

Tokyo, Japan & Strasbourg, France, September 8, 2026 - (JCN Newswire via SeaPRwire.com) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies, today report sustained 100% three-year disease-free…

Hitachi launches new platform and operations management solutions, including HMAX Data Fabric

TOKYO, September 8, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE:6501, "Hitachi"), today launched foundry solutions supporting “HMAX by Hitachi” (“HMAX”), a next-generation suite of solutions that brings the power of AI to social infrastructure. They are the “Physical AI FDE (Forward Deployed Engineer) Service,” in which the “Physical…